Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells

References

• Jain A, Jain SK, Ganesh N, Barve J, Beg AM. (2010). Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine, 6:179–190.
   PubMed Web of Science ®Google Scholar
• Brambilla G, Martelli A. (2009). Genotoxicity and carcinogenicity studies of analgesics, anti-inflammatory drugs and antipyretics. Pharmacol Res, 60:1–17.
   PubMed Web of Science ®Google Scholar
• Deorukhkar A, Krishnan S. (2010). Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol, 80:1904–1914.
   PubMed Web of Science ®Google Scholar
• Naruse T, Nishida Y, Ishiguro N. (2007). Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells. Biomed Pharmacother, 61:338–346.
   PubMed Web of Science ®Google Scholar
• Tsai CS, Luo SF, Ning CC, Lin CL, Jiang MC, Liao CF. (2009). Acetylsalicylic acid regulates MMP-2 activity and inhibits colorectal invasion of murine B16F0 melanoma cells in C57BL/6J mice: Effects of prostaglandin F(2)α. Biomed Pharmacother, 63:522–527.
   PubMed Web of Science ®Google Scholar
• Wu WK, Sung JJ, Lee CW, Yu J, Cho CH. (2010). Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: An update on the molecular mechanisms. Cancer Lett, 295:7–16.
   PubMed Web of Science ®Google Scholar
• Hyde CA, Missailidis S. (2009). Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol, 9:701–715.
   PubMed Web of Science ®Google Scholar
• Sakagami H. (2010). Apoptosis-inducing activity and tumor-specificity of antitumor agents against oral squamous cell carcinoma. Japan Dent Sci Rev, 46:173–187.
   Google Scholar
• Suzuki R, Yamamoto M, Saka H, Taniguchi H, Shindoh J, Tanikawa Y et al. (2009). A phase II study of carboplatin and paclitacel with meloxicam. Lung Cancer, 63:72–76.
   PubMed Web of Science ®Google Scholar
• Dong X, Ke X, Liao Z. (2011). The microstructure characterization of meloxicam microemulsion and its influence on the solubilization capacity. Drug Dev Ind Pharm, 37:894–900.
   PubMed Web of Science ®Google Scholar
• Patel M, Joshi A, Hassanzadeth H, Juluru R, Stagni G. (2011). Quantification of dermal and transdermal delivery of meloxicam gels in rabbits. Drug Dev Ind Pharm, 37:613–617.
   PubMed Web of Science ®Google Scholar
• Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M et al. (1998). Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis, 19:2195–2199.
   PubMed Web of Science ®Google Scholar
• Tsubouchi Y, Mukai S, Kawahito Y, Yamada R, Kohno M, Inoue K et al. (2000). Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res, 20:2867–2872.
   PubMed Web of Science ®Google Scholar
• Kern MA, Schöneweiss MM, Sahi D, Bahlo M, Haugg AM, Kasper HU et al. (2004). Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis, 25:1193–1199.
   PubMed Web of Science ®Google Scholar
• Montejo C, Barcia E, Negro S, Fernández-Carballido A. (2010). Effective antiproliferative effect of meloxicam on prostate cancer cells: Development of a new controlled release system. Int J Pharm, 387:223–229.
   PubMed Web of Science ®Google Scholar
• Hattori K, Iida K, Joraku A, Tsukamoto S, Akaza H, Oyasu R. (2006). Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int, 97:640–643.
   PubMed Web of Science ®Google Scholar
• Naruse T, Nishida Y, Hosono K, Ishiguro N. (2006). Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis, 27:584–592.
   PubMed Web of Science ®Google Scholar
• Wolfesberger B, Walter I, Hoelzl C, Thalhammer JG, Egerbacher M. (2006). Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Res Vet Sci, 80:308–316.
   PubMed Web of Science ®Google Scholar
• Acharya S, Sahoo SK. (2011). PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev, 63:170–183.
   PubMed Web of Science ®Google Scholar
• He C, Hu Y, Yin L, Tang C, Yin C. (2010). Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials, 31:3657–3666.
   PubMed Web of Science ®Google Scholar
• Wang M, Thanou M. (2010). Targeting nanoparticles to cancer. Pharmacol Res, 62:90–99.
   PubMed Web of Science ®Google Scholar
• Malam Y, Loizidou M, Seifalian AM. (2009). Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci, 30:592–599.
   PubMed Web of Science ®Google Scholar
• Song X, Zhao Y, Hou S, Xu F, Zhao R, He J et al. (2008b). Dual agents loaded PLGA nanoparticles: Systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm, 69:445–453.
   PubMed Web of Science ®Google Scholar
• Birnbaum DT, Kosmala JD, Brannon-Peppas L. (2000). Optimization of preparation techniques for poly(lactic acid-co-glycolic acid) nanoparticles. J Nanopart Res, 2:173–181.
   Web of Science ®Google Scholar
• Katsikari A, Patronidou C, Kiparissides C, Arsenakis M. (2009). Uptake and cytotoxicity of poly(D,L-lactide-co-glycolide) nanoparticles in human colon adenocarcinoma cells. Mat Sci Eng B, 165:160–164.
   Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces, 75:1–18.
   PubMed Web of Science ®Google Scholar
• Shi K, Cui F, Yamamoto H, Kawashima Y. (2009). Optimized formulation of high-payload PLGA nanoparticles containing insulin-lauryl sulfate complex. Drug Dev Ind Pharm, 35:177–184.
   PubMed Web of Science ®Google Scholar
• Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. (2002). Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett, 531:278–284.
   PubMed Web of Science ®Google Scholar
• Zhang N, Tao K, Huang T. (2007). Effects of meloxicam on vascular endothelial growth factor and angiopoietin-2 expression in colon carcinoma cell line HT-29. J Huazhong Univ Sci Technol Med Sci, 27:399–402.
   PubMed Web of Science ®Google Scholar
• Gao C, Huang J, Jiao Y, Shan L, Liu Y, Li Y et al. (2006). In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit FS 30 D-coated pellets. Int J Pharm, 322:104–112.
   PubMed Web of Science ®Google Scholar
• McCarron PA, Donnelly RF, Marouf W. (2006). Celecoxib-loaded poly(D,L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure. J Microencapsul, 23:480–498.
   PubMed Web of Science ®Google Scholar
• Budhian A, Siegel SJ, Winey KI. (2007). Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. Int J Pharm, 336:367–375.
   PubMed Web of Science ®Google Scholar
• Klose D, Siepmann F, Elkharraz K, Siepmann J. (2008). PLGA-based drug delivery systems: Importance of the type of drug and device geometry. Int J Pharm, 354:95–103.
   PubMed Web of Science ®Google Scholar
• Sengel CT, Hasçiçek C, Gönül N. (2006). Development and in vitro evaluation of modified release tablets including ethylcellulose microspheres loaded with diltiazem hydrochloride. J Microencapsul, 23:135–152.
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Panyam J, Prabha S, Labhasetwar V. (2002). Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release, 82:105–114.
   PubMed Web of Science ®Google Scholar
• Bayindir ZS, Yuksel N. (2010). Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci, 99:2049–2060.
   PubMed Web of Science ®Google Scholar
• Greulich C, Diendorf J, Simon T, Eggeler G, Epple M, Köller M. (2011). Uptake and intracellular distribution of silver nanoparticles in human mesenchymal stem cells. Acta Biomater, 7:347–354.
   PubMed Web of Science ®Google Scholar
• Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MN. (2007). Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release, 119:77–85.
   PubMed Web of Science ®Google Scholar
• Song X, Zhao Y, Wu W, Bi Y, Cai Z, Chen Q et al. (2008a). PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: Systematic study of particle size and drug entrapment efficiency. Int J Pharm, 350:320–329.
   PubMed Web of Science ®Google Scholar
• Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, Feron O et al. (2009). Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J Control Release, 133:11–17.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Feng SS. (2006). Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: Synthesis, formulation, characterization and in vitro drug release. Biomaterials, 27:262–270.
   PubMed Web of Science ®Google Scholar
• Konan YN, Gurny R, Allémann E. (2002). Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm, 233:239–252.
   PubMed Web of Science ®Google Scholar
• Panyam J, Dali MM, Sahoo SK, Ma W, Chakravarthi SS, Amidon GL et al. (2003). Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release, 92:173–187.
   PubMed Web of Science ®Google Scholar
• Hong K, Nakayama K, Park S. (2002). Effects of protective colloids on the preparation of poly(l-lactide)/poly(butylene succinate) microcapsules. Eur Polym J, 38:305–311.
   Web of Science ®Google Scholar
• Liu Y, Pan J, Feng SS. (2010). Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: Effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm, 395:243–250.
   PubMed Web of Science ®Google Scholar
• Tahara K, Sakai T, Yamamoto H, Takeuchi H, Hirashima N, Kawashima Y. (2009). Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int J Pharm, 382:198–204.
   PubMed Web of Science ®Google Scholar
• Yan F, Zhang C, Zheng Y, Mei L, Tang L, Song C et al. (2010). The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine, 6:170–178.
   PubMed Web of Science ®Google Scholar
• Cegnar M, Premzl A, Zavasnik-Bergant V, Kristl J, Kos J. (2004). Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. Exp Cell Res, 301:223–231.
   PubMed Web of Science ®Google Scholar
• Davda J, Labhasetwar V. (2002). Characterization of nanoparticle uptake by endothelial cells. Int J Pharm, 233:51–59.
   PubMed Web of Science ®Google Scholar